

NEW JERSEY DRUG UTILIZATION REVIEW BOARD
VIRTUAL PLATFORM

April 23, 2025

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of meeting transcript for January 15, 2025, meeting
https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/4-2025/January_2025_DURB_meeting_transcript_updated.pdf
- IV. Review of draft meeting summary for January 15, 2025, meeting (pages 4-8)
- V. Secretary's report (page 9)
- VI. Old Business
 - A. Utilization Trends of SGLT-2 inhibitors, GLP-1/GIP Agonists, and CGRP Inhibitors (pages 10-12)
 - B. Updated protocol for Alopecia Areata products (pages 13-14)
 - C. Updated protocol for Lyfgenia[™] (lovotibeglogene autotemcel) (page 15)
 - D. Updated protocol for Casgevy[®] (exagamglogene autotemcel) (page 16)
- VII. New Business
 - A. Proposed protocol for Attention Deficit Hyperactivity Disorder (ADHD) for children < 6 years old (pages 17-18)
 - B. Proposed protocol for Zepbound[®] (tirzepatide) (pages 19-20)
 - C. Proposed protocol for Spravato[®] (esketamine) (pages 21-23)
- VIII. A. Informational Highlights/Reports
 - 1. Gainwell Technologies/NJ MCO 4th Quarter 2024 Prior Authorization Report (page 24)
 - 2. Summary of DURB Action Items (pages 25-28)
 - 3. DHS/DOH Pharmacy Programs Top Drugs Report/Physicians Administered Drugs Report (by amount paid and by category)

FFS top drugs:

https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/4-2025/FFS_Top_Drugs_Report_January_2025.pdf

MCO top drugs:

https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/4-2025/MCO_Top_Drugs_Report_December_2024.pdf

FFS top drugs by category:

https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/4-2025/FFS_Top_Drugs_by_Category_January_2025.pdf

MCO top drugs by category:

https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/4-2025/MCO_Top_Drugs_by_Category_December_2024.pdf

FFS antiviral drugs:

https://www.nj.gov/humanservices/dmahs/boards/durb/agendas/4-2025/FFS_Antiviral_Drugs_January_2025.pdf

B. Medication/Medical information

1. FDA Approved Journavx™ (suzetrigine), a first-in-class treatment for adults with moderate to severe acute pain

<https://www.fda.gov/news-events/press-announcements/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain>

2. Update to American Diabetes Association Diabetes Guidelines

https://ada.silverchair-cdn.com/ada/content_public/journal/care/issue/48/supplement_1/6/standards-of-care-2025.pdf?Expires=1744317313&Signature=lhEzH38-q8CwB72XbawcXwo1Nkwh10P9B97JedemqjMG4Jifo6vV2~uGJKxEgijLegNRBRmR43C~zmSTpunG-WD1thcGPVzahNr7Wc7-1xDSm38gPAQOoQPcOmQsl4VeLEcR9JtWiCISiumCv5P9~HhZdD1orGatGgV3Ni5-60wfih2lgPQuq1O7HinJPQ~gQVZwfmfOLVsdQS0xSF-~4ql2buJf65cGAZJhnwB9yw~Z3tX06ZBNYS0IdJEyQL198-iEGZ5vKAuYqf4F~N-ZF78Mb2b8yWOZDqT7jnDUfpot2~X4IIrEC4TROL72iXqord7o1yqnoweg--AEIcudhA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA

3. Novo Nordisk Press Release January 28, 2025 – FDA Approves Ozempic™ as the only GLP-1 Receptor Agonist to Reduce the Risk of Worsening Kidney Disease and Cardiovascular Death in Adults with Type 2 Diabetes Mellitus and Chronic Kidney Disease

[https://urldefense.com/v3/_https://www.novonordisk-us.com/media/news-archive/news-details.html?id=915253_!!J30X0ZrnC1oQtbA!KBW7gFEFNm1h17y8nUdUNrmHBZBOLkcc0HpuDpaXfsHc8S9jSoDrnsUIVUIWSjr6ztXtsQrhUsUpwKqaOVE8U0tmpC4ZP31j4AnumYQkecBL\\$](https://urldefense.com/v3/_https://www.novonordisk-us.com/media/news-archive/news-details.html?id=915253_!!J30X0ZrnC1oQtbA!KBW7gFEFNm1h17y8nUdUNrmHBZBOLkcc0HpuDpaXfsHc8S9jSoDrnsUIVUIWSjr6ztXtsQrhUsUpwKqaOVE8U0tmpC4ZP31j4AnumYQkecBL$)

4. Centers for Medicare & Medicaid Services (CMS) Infographic Released October 2024. 2024 Medicaid & CHIP Beneficiaries at a Glance: Attention Deficit/Hyperactivity Disorder

[https://urldefense.com/v3/_https://www.medicaid.gov/medicaid/benefits/downloads/2024-ADHD-infographic.pdf_!!J30X0ZrnC1oQtbA!KBW7gFEFNm1h17y8nUdUNrmHBZBOLkcc0HpuDpaXfsHc8S9jSoDrnsUIVUIWSjr6ztXtsQrhUsUpwKqaOVE8U0tmpC4ZP31j4AnumfuJpeQo\\$](https://urldefense.com/v3/_https://www.medicaid.gov/medicaid/benefits/downloads/2024-ADHD-infographic.pdf_!!J30X0ZrnC1oQtbA!KBW7gFEFNm1h17y8nUdUNrmHBZBOLkcc0HpuDpaXfsHc8S9jSoDrnsUIVUIWSjr6ztXtsQrhUsUpwKqaOVE8U0tmpC4ZP31j4AnumfuJpeQo$)

5. Centers for Disease Control and Prevention (CDC) – State Medicaid Policies Prescribing ADHD Medications to Children

[https://urldefense.com/v3/_https://www.cdc.gov/adhd/media/pdfs/fact-sheet-adhd-medicaid-policies.pdf_!!J30X0ZrnC1oQtbA!KBW7gFEFNm1h17y8nUdUNrmHBZBOLkcc0HpuDpaXfsHc8S9jSoDrnsUIVUIWSjr6ztXtsQrhUsUpwKqaOVE8U0tmpC4ZP31j4Anumdj5hKgO\\$](https://urldefense.com/v3/_https://www.cdc.gov/adhd/media/pdfs/fact-sheet-adhd-medicaid-policies.pdf_!!J30X0ZrnC1oQtbA!KBW7gFEFNm1h17y8nUdUNrmHBZBOLkcc0HpuDpaXfsHc8S9jSoDrnsUIVUIWSjr6ztXtsQrhUsUpwKqaOVE8U0tmpC4ZP31j4Anumdj5hKgO$)